Evolva: Funding, Investors & Team (Sep 2026)
Evolva was founded in 2004 around a distinctive, proprietary, technology platform that uses synthetic biology to create innovative small molecule drugs and other compounds. In particular their platform allows the creation of chemistries that recapitulate the themes found in natural products, but without the disadvantages of those approaches.
Evolva has raised $20.1M across 3 funding rounds on record, the most recent a Grant of $540k announced in Oct 2022.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Evolva Company Profile and Key Stats
Latest funding round on record: Oct 2022.
Evolva Funding Rounds
Evolva raised $13.1M in a Post-IPO Debt announced in Dec 2021.
5 months later, a Post-IPO Equity of $6.5M was announced in May 2022.
5 months later, a Grant of $540k was announced in Oct 2022.
Evolva Founders and Leadership Team
Contact details for the Evolva team: 2 of 2 have an email address on file.
Start 14-day free trial →Evolva Funding Compared to Other Biotechnology Startups
Evolva's latest round of $540k is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Evolva in Biotechnology and Reinach
Companies Similar to Evolva
Adaptyv Biosystems developing a protein engineering platform using cell-free synthetic biology and…
At Immitra Bio, we are developing a unique genetic medicine platform that combines two of the most powerful…
compliag is providing agile solutions for regulated industries, including the licencing, manufacturing and…
MoonLake Immunotherapeutics is a biopharmaceutical company in the clinical stage that is developing new…
Isospec Analytics SA is a life science company that aims at simplifying molecular identification. We are…
Cria Technologies reinvents cold-chain transport with high-vacuum insulation technology that offers…
Precise Health is a phage therapy platform that specialises in improving and treating bacterial infections to…
AC Immune is a biopharmaceutical company based in Switzerland that is currently in the clinical stage. They…
AlveoliX provides in-vitro solutions based on proprietary and unique organ-on-chip technologies aimed at…
Combioxin SA is clinical-stage biotech company developing innovative anti-virulence drugs to treat severe…
MindMaze is a digital neurotherapeutic platform that provides digital assessments and therapeutics to treat…
Neurosoft Bioelectronics is developing next-generation soft implantable electrodes to interface with the…
Evolva Funding FAQs
What does Evolva do?
Evolva was founded in 2004 around a distinctive, proprietary, technology platform that uses synthetic biology to create innovative small molecule drugs and other compounds. In particular their platform allows the creation of chemistries that recapitulate the themes found in natural products, but without the disadvantages of those approaches.
How much funding has Evolva raised?
Evolva has raised $20.1M across 3 rounds on record. The most recent is a Grant of $540k announced in Oct 2022.
When did Evolva last raise funding?
Evolva's most recent funding round on record is a Grant of $540k, announced in Oct 2022.
Who is the CEO of Evolva?
Christian Wichert is listed as CEO at Evolva.
Where is Evolva headquartered?
Evolva is based in Reinach, Aargau, Switzerland.
How many employees does Evolva have?
Evolva is in the 101-250 employee band.
How does Evolva's funding compare to other Biotechnology startups?
Evolva's latest round of $540k is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Evolva Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Evolva is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.